Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evaluation of the potential for QTc prolongation with avelumab.
Vugmeyster Y, Güzel G, Hennessy M, Loos AH, Dai H. Vugmeyster Y, et al. Among authors: guzel g. Cancer Chemother Pharmacol. 2019 Nov;84(5):1017-1026. doi: 10.1007/s00280-019-03925-z. Epub 2019 Sep 3. Cancer Chemother Pharmacol. 2019. PMID: 31478078 Free PMC article.
Health-related quality of life trajectory of treatment-naive patients with Merkel cell carcinoma receiving avelumab.
Bharmal M, Nolte S, Lebbé C, Mortier L, Brohl AS, Fazio N, Grob JJ, Pusceddu S, Hanna GJ, Hassel JC, Kiecker F, Ellers-Lenz B, Bajars M, Güzel G, Nghiem P, Hunger M, Schlichting M, Henry-Szatkowski M, D'Angelo SP. Bharmal M, et al. Among authors: guzel g. Future Oncol. 2020 Sep;16(27):2089-2099. doi: 10.2217/fon-2020-0426. Epub 2020 Sep 17. Future Oncol. 2020. PMID: 32938212 Free PMC article.
Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial.
D'Angelo SP, Bhatia S, Brohl AS, Hamid O, Mehnert JM, Terheyden P, Shih KC, Brownell I, Lebbé C, Lewis KD, Linette GP, Milella M, Georges S, Shah P, Ellers-Lenz B, Bajars M, Güzel G, Nghiem PT. D'Angelo SP, et al. Among authors: guzel g. J Immunother Cancer. 2020 May;8(1):e000674. doi: 10.1136/jitc-2020-000674. J Immunother Cancer. 2020. PMID: 32414862 Free PMC article. Clinical Trial.
First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study.
D'Angelo SP, Lebbé C, Mortier L, Brohl AS, Fazio N, Grob JJ, Prinzi N, Hanna GJ, Hassel JC, Kiecker F, Georges S, Ellers-Lenz B, Shah P, Güzel G, Nghiem P. D'Angelo SP, et al. Among authors: guzel g. J Immunother Cancer. 2021 Jul;9(7):e002646. doi: 10.1136/jitc-2021-002646. J Immunother Cancer. 2021. PMID: 34301810 Free PMC article. Clinical Trial.
Patient Experiences with Avelumab in Treatment-Naïve Metastatic Merkel Cell Carcinoma: Longitudinal Qualitative Interview Findings from JAVELIN Merkel 200, a Registrational Clinical Trial.
Lambert J, Marrel A, D'Angelo SP, Burgess MA, Chmielowski B, Fazio N, Gambichler T, Grob JJ, Lebbé C, Robert C, Russell J, Güzel G, Bharmal M. Lambert J, et al. Among authors: guzel g. Patient. 2020 Aug;13(4):457-467. doi: 10.1007/s40271-020-00428-5. Patient. 2020. PMID: 32472503 Free PMC article. Clinical Trial.
First-line avelumab treatment in patients with metastatic Merkel cell carcinoma: 4-year follow-up from part B of the JAVELIN Merkel 200 study.
D'Angelo SP, Lebbé C, Mortier L, Brohl AS, Fazio N, Grob JJ, Prinzi N, Hanna GJ, Hassel JC, Kiecker F, von Heydebreck A, Güzel G, Nghiem P. D'Angelo SP, et al. Among authors: guzel g. ESMO Open. 2024 May;9(5):103461. doi: 10.1016/j.esmoop.2024.103461. Epub 2024 May 13. ESMO Open. 2024. PMID: 38744102 Free PMC article. Clinical Trial.
16 results